- $11.29m
- $9.78m
- $5.20m
Brief: Organicell Begins Up-Listing Process On Nasdaq
Brief: Organicell Announces Positive Results Of Initial Covid-19 Zofin™ Patient Trial In India And Trial Expansion
Brief: Organicell Completes Enrollment For Its Expanded Access Trial To Treat Covid-19 Patients With Zofin™
Brief: Organicell Announces FDA Approval Of IND Application For Use Of Zofin In The Treatment Of Chronic Obstructive Pulmonary Disease
Brief: Organicell Says FDA Granted Expanded Access To Treat COVID-19 Patients With Zofin
Brief: Organicell Regenerative Medicine - FDA Granted Emergency, Expanded Access Approval To Treat 2 Mild To Moderate Covid-19 Patients
Brief: Organicell Announces FDA Approval Of Ind Application For The Treatment Of Sars Due To Covid-19